TITLE

2011 - Review: Oral phosphodiesterase 4 inhibitors reduce exacerbations but increase adverse events in COPD

AUTHOR(S)
Ram, Felix S.F.
PUB. DATE
September 2011
SOURCE
ACP Journal Club;9/20/2011, Vol. 155 Issue 3, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Question What are the efficacy and safety of oral phosphodiesterase 4 (PDE[sub 4]) inhibitors in patients with stable chronic obstructive pulmonary disease (COPD)? Review scope Included studies compared oral PDE[sub 4] inhibitors (roflumilast or cilomilast) with placebo in patients é>18 years of age with COPD (FEV[sub 1] after bronchodilation <>80% of predicted value, ratio of FEV[sub 1] to FVC >70%). Exclusion criteria included single-dose trials, patients with acute exacerbations, and patients requiring mechanical ventilation. Primary outcomes were lung function (e.g., FEV[sub 1]) and quality of life (QOL) (St. Georges Respiratory Questionnaire [SGRQ] total score, lower scores = better QOL); other outcomes included exacerbations and adverse events. Review methods Cochrane Airways Group Specialized Register, US Food and Drug Administration Web site, and US National Institutes of Health clinical trials registry were searched to August 2010 for randomized controlled trials (RCTs). Reference lists were hand-searched, and authors and drug companies were contacted. 23 RCTs (n =>15>668) met the selection criteria: 9 assessed roflumilast (n =>9211), and 14 assessed cilomilast (n =>6457). 7 roflumilast trials reported adequate allocation concealment, and 6 described method of blinding; no cilomilast trials reported adequate concealment or described method of blinding. Main results Meta-analysis showed that PDE[sub 4] inhibitors improved FEV[sub 1] (21 comparisons, n =>14>307, mean difference in change in FEV[sub 1] 46 mL, 95% CI 39 to 52) and QOL (11 comparisons, n =>7898, mean difference in change in SGRQ total score 1.04, CI 1.66 to 0.41) and reduced exacerbations (Table) compared with placebo. Overall, PDE[sub 4] inhibitors increased risk for adverse events, specifically diarrhea, nausea, vomiting, and headache (Table). Drug-specific meta-analyses showed that cilomilast, 15 mg twice daily, increased vomiting (relative risk increase [RRI] 283%, CI 169 to 445), dyspepsia (RRI 197%, CI 121 to 299), and abdominal pain (RRI 86%, CI 50 to 132); roflumilast, 500 &Bgr;g/d, increased weight loss (RRI 326%, CI 216 to 474). Conclusion In patients with stable chronic obstructive pulmonary disease, oral phosphodiesterase 4 inhibitors reduce exacerbations but increase adverse events.
ACCESSION #
69709874

 

Related Articles

  • Roflumilast in the management of chronic obstructive pulmonary disease. LIPARI, MELISSA; BENIPAL, HARPREET; KALE-PRADHAN, PRAMODINI // American Journal of Health-System Pharmacy;12/1/2013, Vol. 70 Issue 23, p2087 

    Purpose. The pharmacology, pharmacokinetics, efficacy, and safety of roflumilast- the first in a new class of agents for managing chronic obstructive pulmonary disease (COPD)-are reviewed. Summary. Roflumilast (Daliresp, Forest Pharmaceuticals) is an oral phosphodiesterase-4 (PDE-4) inhibitor...

  • 2011 - Review: Inpatient comprehensive geriatric assessment improves the likelihood of living at home at 12 months. Barer, David // ACP Journal Club;12/20/2011, Vol. 155 Issue 6, p1 

    The article focuses on a review of randomized controlled trials (RCTs) which examined if inpatient comprehensive geriatric assessment (CGA) increases the likelihood of living at home after hospital discharge. The meta-analysis revealed that CGA improves the likelihood of living at home following...

  • Asthma drug also reduces COPD exacerbations.  // Pulse;5/18/2011, Vol. 71 Issue 18, p11 

    The article reports on the role of asthma drugs, such as an oral phosphodiesterase-4 (PDE4) inhibitors roflumilast or cilomast, in improving lung function and reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD).

  • Roflumilast: A Review in COPD. Garnock-Jones, Karly // Drugs;Sep2015, Vol. 75 Issue 14, p1645 

    Roflumilast (Daliresp, Daxas) is a selective phosphodiesterase 4 (PDE4) inhibitor that decreases systemic and pulmonary inflammation and improves disease symptoms in patients with severe chronic obstructive pulmonary disease (COPD). This article reviews the pharmacological properties of...

  • Reduction of exacerbations by the PDE4 inhibitor roflumilast - the importance of defining different subsets of patients with COPD. Rennard, Stephen I.; Calverley, Peter M. A.; Goehring, Udo M.; Bredenbröker, Dirk; Martinez, Fernando J. // Respiratory Research;Jan2011, Vol. 12 Issue 1, p18 

    Background: As chronic obstructive pulmonary disease (COPD) is a heterogeneous disease it is unlikely that all patients will benefit equally from a given therapy. Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, has been shown to improve lung function in moderate and severe COPD...

  • Erratum for "Roflumilast, a Novel Phosphodiesterase 4 Inhibitor, for COPD Patients with a History of Exacerbations". Field, Stephen K. // Clinical Medicine Insights: Circulatory, Respiratory & Pulmonary;2012, Issue 6, p51 

    A correction to the article "Roflumilast, a Novel Phosphodiesterase 4 Inhibitor, for COPD Patients with a History of Exacerbations" that was published in the 2011 issue is presented.

  • A novel selective PDE-4 inhibitor for COPD. Mintz, Matthew // Patient Care;Apr2006, Vol. 40 Issue 4, p56 

    Presents the results of a study on the effects of cilomilast, a selective phosphodiesterase 4 inhibitor, on chronic obstructive pulmonary disease (COPD). Average change in forced expiratory volume in 1 second from baseline over 24 weeks; Effectiveness of cilomilast in reducing the rate of COPD...

  • Roflumilast (Daliresp) for Chronic Obstructive Pulmonary Disease. BAZALDUA, ORALIA V.; DAVIDSON, DEWAYNE A.; BABB, FRANKLYN C. // American Family Physician;2/15/2014, Vol. 89 Issue 4, p300 

    This article evaluates the oral selective phosphodiesterase-4 inhibitor Roflumilast (Daliresp) for chronic obstructive pulmonary disease (COPD).

  • Roflumilast, a Novel Phosphodiesterase 4 Inhibitor, for COPD Patients with a History of Exacerbations. Field, Stephen K. // Clinical Medicine Insights: Circulatory, Respiratory & Pulmonary;2011, Issue 5, p57 

    Acute exacerbations of COPD (AECOPD) are major clinical events. They are associated with a more rapid decline in lung function, poorer quality of life scores, and an increased risk of dying. Exacerbations that require hospitalization have particular significance. Approximately 40% of the AECOPD...

  • Vulnerable COPD patients with comorbidities: the role of roflumilast. Lipari, Melissa; Kale-Pradhan, Pramodini B. // Therapeutics & Clinical Risk Management;2014, Vol. 10, p969 

    Roflumilast is a selective phosphodiesterase-4 (PDE-4) inhibitor that was approved by the US Food and Drug Administration in February 2011 for the management of chronic obstructive pulmonary disease (COPD). Literature was retrieved through PubMed using the terms "roflumilast" and "COPD"....

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics